Skip to Content
Fund Spy: Morningstar Medalist Edition

More Winners and Losers Among Funds With Morningstar Analyst Ratings

A look at a few unusual performance and sales patterns among our Morningstar Medalists.

Mentioned: , , , , , , , , ,

'Tis the season for summing up. My colleague Russel Kinnel recently listed 2014's mutual fund winners and losers, and the annual Morningstar Fund Manager of the Year awards are in the works. We've already written about some of the contenders for the domestic and international stock, fixed-income, allocation, and alternative prizes and will announce the finalists and winners in January. Until then, here are some other less-obvious observations on the 2014 performance and fund flows of some of the more than 1,000 funds with Morningstar Analyst Ratings.

Best Equity Fund Performance by a Non-India, Non-Real-Estate, Non-Health-Care, Non-Primecap-Run Fund
Bronze-rated  Matthews India (MINDX) was the best-performing rated equity fund with a 60% gain through Dec. 18 on the back of a gigantic Indian stock market rally. The real estate and health-care sectors enjoyed strong rallies, too, with Bronze-rated  Nuveen Real Estate Securities (FARCX) and Gold-rated  Vanguard Health Care (VGHCX) showing up a bit behind with still-impressive gains of around 30% each.

Dan Culloton has a position in the following securities mentioned above: VGHCX, DODFX, PTTRX, VFINX. Find out about Morningstar’s editorial policies.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.